Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cybin Inc. (HELP : NSDQ)

• Company Description    Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $7.10 Daily Weekly Monthly 20 Day Moving Average: 508,124 shares Shares Outstanding: 49.89 (millions) Market Capitalization: $354.25 (millions) Beta: 0.63 52 Week High: $9.83 52 Week Low: $4.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.96% -6.04% 12 Week 17.75% 16.57% Year To Date -13.20% -13.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 KING STREET WEST SUITE 5600 - TORONTO,A6 M5X 1C9 CAN ph: 908-764-8385 fax: - ir@cybin.com http://www.cybin.com

• General Corporate Information    Officers Douglas Drysdale - Chief Executive Officer Eric So - President Aaron Bartlone - Chief Operating Officer Greg Cavers - Chief Financial Officer Eric Hoskins - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 23256X407 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 06/29/26 Share - Related Items Shares Outstanding: 49.89 Most Recent Split Date: 9.00 (0.03:1) Beta: 0.63 Market Capitalization: $354.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -89.47% vs. Previous Quarter: 48.20% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -59.98 09/30/25 - -55.10 06/30/25 - -56.04 ROA 12/31/25 - -50.80 09/30/25 - -45.94 06/30/25 - -49.54 Current Ratio 12/31/25 - 13.78 09/30/25 - 8.58 06/30/25 - 9.87 Quick Ratio 12/31/25 - - 09/30/25 - 8.58 06/30/25 - 9.87 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 5.49 09/30/25 - 5.52 06/30/25 - 6.43 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.21 06/30/25 - 0.29 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 17.21 06/30/25 - 22.67

Powered by Zacks Investment Research ©